


Treatment with N-acetyl-L-leucine beneficial for Niemann-Pick disease

February 1 2024, by Elana Gotkine



Treatment with N-acetyl-L-leucine (NALL) for 12 weeks yields better neurological status than placebo among patients with genetically confirmed Niemann-Pick disease type C, according to a study published in the Feb. 1 issue of the *New England Journal of Medicine*.



Tatiana Bremova-Ertl, M.D., Ph.D., from the University Hospital Bern in Switzerland, and colleagues randomly assigned 60 patients age 4 years or older with genetically confirmed Niemann-Pick disease type C to receive 12 weeks of NALL followed by 12 weeks of placebo or to receive 12 weeks of placebo followed by 12 weeks of NALL in a 1:1 ratio.

The researchers found that the mean change from baseline in the Scale for the Assessment and Rating of Ataxia total score was -1.97 ± 2.43 and -0.60 ± 2.39 points after 12 weeks of receiving NALL and placebo, respectively (least-squares mean difference, -1.28 points). For the secondary end points, the results were generally supportive of the findings in the primary analysis; however, these were not adjusted for multiple comparisons. A similar incidence of adverse events was seen with NALL and placebo; there were no treatment-related serious adverse events reported.

"In this phase 3 trial involving <u>patients</u> with Niemann-Pick disease type C, <u>treatment</u> with NALL reduced neurologic signs and symptoms as compared with <u>placebo</u> over 12 weeks," the authors write.

More information: Tatiana Bremova-Ertl et al, Trial of N-Acetyl-l-Leucine in Niemann–Pick Disease Type C, *New England Journal of Medicine* (2024). DOI: 10.1056/NEJMoa2310151

Cynthia J. Tifft et al, N-Acetyl-l-Leucine and Neurodegenerative Disease, *New England Journal of Medicine* (2024). DOI: 10.1056/NEJMe2313791

2024 HealthDay. All rights reserved.

Citation: Treatment with N-acetyl-L-leucine beneficial for Niemann-Pick disease (2024,



February 1) retrieved 9 May 2024 from <u>https://medicalxpress.com/news/2024-02-treatment-acetyl-leucine-beneficial-niemann.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.